Chugai Pharmaceutical lifts revenue and profit, full-year results seen beating forecast
Chugai Pharmaceutical grew nine-month revenue 14.1% and core operating profit ran ahead of forecast. TradingView reports that full-year results are expected to exceed the forecast.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, Chugai Pharmaceutical's nine-month revenue grew 14.1%, while core operating profit climbed to 336.1 billion yen. Performance came in ahead of the company's forecast.
The company also targets a Hemlibra auto-injector launch in 2027, and its divarasib compound posted positive Phase III results.
why it matters
Results ahead of forecast after nine months support expectations that full-year figures will exceed the company's outlook. Positive divarasib data strengthen Chugai's oncology pipeline over the coming years.
market impact
Chugai shares: strong results and outlook support the company's stock
- Chugai Pharmaceutical shares pressure up — core operating profit beat forecast and full-year results may exceed it
tags
instruments
sources
- Chugai Pharmaceutical : Revenue and profit advanced; full-year results are expected to exceed forecast — TradingView, 27 October 2026 at 23:20 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗